# Transthyretin Amyloidosis Outcome Survey (THAOS)

> **NCT00628745** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 6718 (actual)

## Conditions studied

- Transthyretin Gene Mutations
- Transthyretin Amyloidosis

## Interventions

- **OTHER:** None. Observational Study.

## Key facts

- **NCT ID:** NCT00628745
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-04
- **Primary completion:** 2023-06-16
- **Final completion:** 2023-06-19
- **Target enrollment:** 6718 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628745, "Transthyretin Amyloidosis Outcome Survey (THAOS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00628745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*